Avalanche Biotechnologies Inc., of Menlo Park, Calif., said it closed its initial public offering (IPO) of 6,900,000 shares of its common stock at $17 each, which included the exercise in full by the underwriters of their option to purchase up to 900,000 additional shares of common stock.